BioCardia, Inc. (BCDA) stock

BCDANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30

$0.83−0.10 (-10.38%)

Close on Nov 12, 2026Market cap $12.50MP/E –Yield –

BioCardia price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

BioCardia's price to sales ratio was 249.1× on Apr 30, 2025, against 19.4× a year earlier. Over the last 3 years it ranged from 11.6× to 499.9×, with a median of 274.1×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2025	Apr 30, 2025	249.1×	+110.2
2024	Dec 31, 2024	138.9×	−236.6
2023	Dec 29, 2023	375.5×	−46.6
2022	Dec 30, 2022	422.1×	−77.8
2021	Dec 31, 2021	499.9×	+18.1
2020	Jul 31, 2020	481.8×	–